Krishnan et al. demonstrated that CRISPR-Cas9 can be used to delete the C9orf72 promoter in motor neurons from ALS/FTD patients, abolishing the production of DPRs and rescuing neurodegeneration associated with ALS [81]. The gene discussed is C9orf72; the disease is frontotemporal dementia.